Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from ...

Vera Therapeutics recently announced positive results from its Phase 3 ORIGIN trial of atacicept in adults with immunoglobulin A nephropathy (IgAN), highlighting a 42% reduction in proteinuria ...

Vera Therapeutics (VERA) announced data from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy were presented as a featured late-breaking ...

RIDE-001, a first-in-class nanomedicine, effectively trained myeloid progenitor cells to elicit myeloid-driven anticancer innate immune responses, as demonstrated in preclinical studies across ...